Chemotherapy Plus Bone Marrow Transplantation and Filgrastim in Treating Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome

Completed · Phase 2

Conditions studied: Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases

In brief

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing and die. Bone marrow transplantation may be able to replace cells that were destroyed by chemotherapy. Colony-stimulating factors such as filgrastim may increase the number of immune cells found in bone marrow or peripheral blood and may help a person's immune system recover from the side effects of chemotherapy. PURPOSE: Phase II trial to study the effectiveness of chemotherapy plus bone marrow transplantation and filgrastim in treating patients who have acute myelogenous leukemia or myelodysplastic syndrome.

Key facts

Study ID

NCT00004899

Run by

Northwestern University

Starts

1999-10-01

Expected to finish

2004-08-01

Last updated by the study team

2012-06-12

Who can join

Age: any, up to 65. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Robert H. Lurie Comprehensive Cancer Center at Northwestern University — Chicago, Illinois, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.